Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cryoport, Inc.    CYRX


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Cryoport : Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell and Gene Therapy

share with twitter share with LinkedIn share with facebook
share via e-mail
11/06/2019 | 09:01am EST

Basel - Lonza (SWX: LONN) and Cryoport, Inc. (NASDAQ: CYRX) ('Cryoport'), announced today their partnership in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network.

As a part of this commitment, Lonza announced Cryoport as its preferred partner in the transport and delivery of patient tissues on a global basis, with the continued goal of seamless service for Lonza's customers and their patients. Lonza and Cryoport will work to remove the supply chain hurdles faced by developers of personalized therapeutics-including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines-as they prepare for the commercial launch of their respective therapies.

Lonza's network of cell and gene therapy facilities spans the US, Europe and Asia and serves both clinical and commercial customers globally. Cryoport currently supports over 413 clinical trials and 3 commercial therapies in the regenerative medicine space and operates in over 100 countries around the world. Integrating Cryoport's logistics andbioservices solutions with Lonza's manufacturing services and expertise will ensure a trusted and seamless supply chain and drive efficiencies in delivering innovative medicines to patients.

The goal of the partnership is to provide fully integrated solutions including, but not limited to, co-location of manufacturing, bioservices and distribution facilities to improve and enhance responsiveness and optimized product workflow, automated data management providing integrated data entry, and process optimization that reduces risk, increases transparency and improves certainty.

Cryoport's logistics system aims to provide Lonza's clients with reliable and comprehensive delivery solutions through its advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting teams of professionals. Beyond Cryoport's proprietary Cryoport Express Shippers, this partnership incorporates Cryoport's Cryoportal Logistics Management Platform and SmartPak II Condition Monitoring System, which brings to the market an integrated IT solution that provides risk mitigation and Cryoport's unique Chain of Compliance for regulatory solutions.

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum . Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.

About Cryoport

Cryoport, Inc. (Nasdaq: CYRX) is the world's premier provider of temperature-controlled supply chain solutions for the life sciences industry, serving the Biopharma, Human Reproductive, and Animal Health markets. Our mission is to support life and health on earth by providing reliable and comprehensive solutions for the life sciences through our advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting team of professionals. Through purpose-built proprietary packaging; information technology; smart, sustainable cold chain logistics and biostorage/biobanking services, Cryoport helps its customers advance life sciences research, support life-saving advanced therapies and deliver vaccines, protein producing materials, and IVF treatments in over 100 countries around the world.


Dr. Kristin Koehler

Tel: +41 61 316 8782

Additional Information and Disclaimer (Lonza)

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Forward Looking Statements (Cryoport)

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Company's 10-K for the year ended December 31, 2018 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

(C) 2019 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CRYOPORT, INC. 2.38% 15.04 Delayed Quote.36.36%
LONZA GROUP -0.24% 335.6 Delayed Quote.32.08%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CRYOPORT, INC.
11/07CRYOPORT, INC. : Results of Operations and Financial Condition, Financial Statem..
11/07CRYOPORT : Revenue Grows 81% for Third Quarter 2019
11/06CRYOPORT : Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Deliv..
11/05CRYOPORT : Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Deliv..
10/30CRYOPORT, INC. : Change in Directors or Principal Officers, Financial Statements..
10/28VIDEO : Complying with Critical Regulations: Cryoport's Chain of Compliance &tra..
10/10ADAPTIMMUNE THERAPEUTICS : and Cryoport Announce Agreement to Ensure Safe and Fu..
10/09CRYOPORT : As Cell Therapy Approvals Speed Up, Companies Struggle with Manufactu..
10/09CRYOPORT, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
More news
Financials (USD)
Sales 2019 35,1 M
EBIT 2019 -17,0 M
Net income 2019 -19,5 M
Finance 2019 79,0 M
Yield 2019 -
P/E ratio 2019 -25,9x
P/E ratio 2020 -89,3x
EV / Sales2019 13,1x
EV / Sales2020 8,06x
Capitalization 539 M
Duration : Period :
Cryoport, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CRYOPORT, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 6
Average target price 25,50  $
Last Close Price 15,04  $
Spread / Highest target 99,5%
Spread / Average Target 69,5%
Spread / Lowest Target 59,6%
EPS Revisions
Jerrell W. Shelton Chairman, President & Chief Executive Officer
Phil Wilson SVP-Global Operations & Supply Chain
Robert S. Stefanovich Chief Financial Officer, Secretary & Treasurer
Bret Bollinger Chief Technology Officer
Edward J. Zecchini Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CRYOPORT, INC.36.36%539
DEUTSCHE POST AG44.79%47 579
DSV A/S75.49%25 844